Current opportunities
Where consumer healthcare is heading next — and where we can take you.
The next decade of consumer healthcare will not be won in crowded multivitamin aisles. It will be won in emerging, science-driven categories where consumer demand is running ahead of the products available on the shelf. e-conn maintains an active portfolio of European medical devices and food supplements in precisely these segments — each with a sound scientific dossier and defensible health claims, ready for the right partner. The categories below are open now. They will not remain open long.
1 · GLP-1 era & metabolic health
The GLP-1 revolution has redrawn the map of consumer health. The market for nutritional products supporting GLP-1 users alone stands at USD 3.5 billion in 2025 and is forecast to reach USD 6.9 billion by 2031, growing at over 12% annually — the fastest-emerging category in the industry, spanning appetite and metabolic support, muscle preservation and liver health. Millions of consumers now think in terms of satiety, sarcopenia and fatty liver; very few shelves answer them. We hold portfolio-ready solutions for this space.
2 · Longevity & healthy ageing
Longevity has moved from science journals to shopping baskets. The global longevity-supplements market reached USD 8.75 billion in 2025, after growing at roughly 10.5% per year, and is projected to hit USD 14.3 billion by 2030. Cellular health, senescence and autophagy are the new consumer vocabulary — and the first brands to own these words in each market will own the category. We can put credible, claim-supported products behind them.
3 · Gastrointestinal health
The gut remains consumer healthcare’s most reliable engine. The global digestive-health supplements market was valued at USD 14.1 billion in 2024 and is projected to more than double to USD 29.9 billion by 2033, at a CAGR of 8.7%. Beyond generic probiotics, the growth sits in targeted solutions — IBS, IBD support, flatulence, constipation and reflux — where substance-based medical devices with treatment claims outperform commodity supplements. Our portfolio covers each of these niches.
4 · Women’s health
One of the decade’s defining categories: women’s health was the second-fastest-growing supplement category worldwide over the past decade, at nearly 10% CAGR, and the global women’s health supplements market — USD 41.1 billion in 2023 — is heading toward USD 66.5 billion by 2032, with the menopause segment alone approaching USD 19 billion in 2025 and growing at over 6% annually. Menopause, PCOS and intimate health remain dramatically underserved in most pharmacies. We have products waiting for the companies willing to serve them.
5 · Mood & memory
Mental performance has become a mainstream purchase. The brain-health supplements market stands at USD 12.6 billion in 2025 and is projected to nearly triple to USD 35.9 billion by 2035, at a CAGR above 11% — driven by mood and stress support on one side and cognitive performance on the other, from students to executives to the worried-well over fifty. Few categories reward scientific credibility more richly; few punish weak products faster.
6 · Dermatology & beauty-from-within
The global nutricosmetics market reached USD 7.1 billion in 2024 and is forecast to grow at 7.9% annually to USD 13.1 billion by 2032, while topical solutions for atopic-prone and problem skin migrate steadily from prescription to self-care. The winning formula combines dermocosmetic positioning with genuine evidence — exactly the intersection our portfolio occupies.
7 · Paediatrics
Screens have made eye care an everyday concern. The eye-health supplements market, valued at USD 2.6 billion in 2023, is growing at 7.3% annually toward USD 4.8 billion by 2032. Dry eye, allergy-prone eyes and macular health each offer room for differentiated devices and supplements — a compact category with pharmacist recommendation at its heart, ideal for companies seeking defensible niches.
8 · Ophthalmology
Screens have made eye care an everyday concern. The eye-health supplements market, valued at USD 2.6 billion in 2023, is growing at 7.3% annually toward USD 4.8 billion by 2032. Dry eye, allergy-prone eyes and macular health each offer room for differentiated devices and supplements — a compact category with pharmacist recommendation at its heart, ideal for companies seeking defensible niches.
9 · Cough, cold & immunity
The pharmacy’s oldest category is renewing itself. Cold-and-flu supplements represent an USD 18.5 billion global market heading toward USD 27.5 billion by 2033, and immune-health supplements — USD 25.3 billion in 2023 — are compounding at 9.8% annually. Consumers increasingly want symptom management and immune support from mechanisms they can trust — a demand substance-based medical devices are exceptionally well placed to meet.
Nine categories. One conversation
Every product behind these categories has passed our four-part Product Matrix: the science, the regulatory route, the margin and the partner fit. These windows are open now — and in emerging categories, the advantage belongs to the company that moves first, not the one that moves carefully a year later. Tell us which segment belongs in your portfolio, and we will show you what is available for your market.
Market figures compiled from publicly available industry research (Mordor Intelligence, Global Market Insights, Straits Research, IMARC, Towards Healthcare and others, 2024–2026). Category descriptions address business audiences and do not constitute product claims.